News
BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results